Clinical trial failures

Sponsor hub

Bayer clinical trial failures

Review 77 stopped clinical trials from Bayer, including disease areas, phases, and classified stop reasons.

This page groups real ClinicalTrials.gov-derived stopped trial records. The strongest added signal is the stop-reason classification: 8 of these records are likely biological failure signals, while the rest may reflect operational, strategic, regulatory, funding, enrollment, or unclear stop reasons.

Total stopped trials77
Likely biological signals8
Shown below77

Dominant stop reasons

OTHER/UNKNOWN
56
OPERATIONAL
13
EFFICACY/FUTILITY
4
SAFETY
4

Notable sponsors

Bayer
77

Related phases

Phase I
27
Phase II
25
Phase III
19
Phase IV
4
Unknown
2

Crawlable stopped-trial records

Open Explore

Showing up to 77 representative records from this slice. Each link opens the trial detail page with source attribution and stop-reason context.

NCT04999202: A Study to Learn How Safe the Study Drug BAY 2416964 (AhR Inhibitor) in Combination With the Treatment Pembrolizumab is, How This Combination Affects the Body, the Maximum Amount That Can be Given, How it Moves Into, Through and Out of the Body and Its Action Against Advanced Solid Cancers in Adults

Phase I Advanced Solid Tumors trial by Bayer. Stop reason: OTHER/UNKNOWN.

Last patient ongoing on treatment ended the study on 20th January 2025. Hence, the end of study was reached as defined in the protocol.

NCT03996473: Study to Test the Safety and How Radium-223 Dichloride an Alpha Particle-emitting Radioactive Agent Works in Combination With Pembrolizumab an Immune Checkpoint Inhibitor in Patients With Stage IV Non-small Cell Lung Cancer With Bone Metastases

Phase I Carcinoma, Non-Small-Cell Lung trial by Bayer. Stop reason: OPERATIONAL.

LPLV reached on 30Jan2023. Study was closed early for feasibility reasons related to enrollment of first line IO naïve patients. Safety data is consistent with the known safety profile of both drugs and no new safety issues have been observed

NCT04809805: A Study to Learn How Safe BAY2666605 is, How it Affects the Body, How it Moves Into, Through and Out of the Body, the Maximum Amount That Can be Given and Its Action Against Tumors in Adult Participants With Skin Cancer That Has Spread to Other Parts of the Body and Other Types of Advanced Cancer

Phase I Metastatic Melanoma and Other Solid Tumors trial by Bayer. Stop reason: OTHER/UNKNOWN.

Due to the high probability of not achieving a therapeutic window and lack of evidence of sufficient clinical benefit.

NCT04417036: This Study Collects Information on the Safety of Inhaled Pegylated Adrenomedullin (PEG-ADM), How the Drug is Tolerated and How it Affects Patients Suffering From a Type of Lung Failure That Cause Fluid to Build up in the Lungs Making Breathing Difficult (ARDS)

Phase II Acute Respiratory Distress Syndrome trial by Bayer. Stop reason: OTHER/UNKNOWN.

Terminated (based on Part A results, Bayer decided to not continue investigating BAY 1097761 further in Part B; this was not due to any safety data for BAY 1097761)